Th9507

[ZCorker]

Has anyone heard when the next Th9507 trial is going to start in California?  I have been on a 6 drug cocktail and my viral load is the lowest it has ever been, but my percentage of lymphocytes is no longer climbing.  I am locked in at 16% and I would feel a lot more comfortable if they were above 20%.  I ended up going all the way down to 77 T-Cells at less than 9% prior to starting medications in February 2008.  I had substantial drug resistance.

Let me know about Th9507.

ZC
 

[veritas]

http://clinicaltrials.gov/ct2/show/NCT00608023

I don't think this will help with your viral load or cd4 count, but here is the latest clinical trial.

[MitchMiller]

Z:  You probably wouldn't have posted if you weren't already familiar with the Gladstone Inst. studies showing HGH increases TCell counts... and not in the same way as IL2, but rather in "de-aging" the thymus.  I would like to see TCell counts published from the lipo studies of this HGH pro-drug.  I would expect they are in the complete results, but not in the summarized abstracts that are published in the press. 

Here's just a reminder about the basis for why Th9507 should be studied as an agent to enhance the immune system:

 AIDS. 2002 May 24;16 (:1103-11 12004268 (P,S,G,E,B) Cited:3
[Cited?]
Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone.
[My paper] Laura A Napolitano, Joan C Lo, Michael B Gotway, Kathleen Mulligan, Jason D Barbour, Diane Schmidt, Robert M Grant, Robert A Halvorsen, Morris Schambelan, Joseph M McCune
Gladstone Institute of Virology and Immunology, University of California at San Francisco, San Francisco, CA 94141, USA.
OBJECTIVE: To determine whether treatment with growth hormone (GH) enhances thymopoiesis in individuals infected with HIV-1. METHODS: Five HIV-1-infected adults were treated with GH for 6-12 months in a prospective open-label study. Immunological analyses were performed before GH treatment and repeated at 3 month intervals after GH initiation. Thymic mass was analysed using computed tomography with quantitative density and volume analysis. Analysis of circulating lymphocytes, including naive and memory T cell subsets, was performed using multiparameter flow cytometry. RESULTS: GH treatment was associated with a marked increase in thymic mass in all GH recipients. Circulating naive CD4 T cells also increased significantly in all patients during GH therapy, suggesting an enhancement of thymopoiesis. CONCLUSION: GH has significant effects on the human immune system, including the reversal of thymic atrophy in HIV-1-infected adults. De-novo T cell production may thus be inducible in immunodeficient adults.